Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) (CoV-Early)
Sponsor: Erasmus Medical Center
Terminated
vaccination uptake 80% in the target population/new COVID variant
This PHASE3 trial investigates Covid19 and is currently terminated or withdrawn. Erasmus Medical Center leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jan 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Leiden University Medical Center
- Prothya Biosolutions
- ZonMw: The Netherlands Organisation for Health Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .